The FDA has granted marketing clearance for sexually transmitted disease testing on Gen-Probe’s TIGRIS® DTS™ system, a fully automated, high throughput instrument for the molecular diagnostics marketplace. The system has been approved to run the company’s APTIMA COMBO 2® assay, an FDA approved amplified nucleic acid test (NAT) for simultaneously detecting chlamydia trachomatis and neisseria gonorrhoeae.
The TIGRIS DTS system, which automates NAT testing from start to finish, requires no manual sample preparation to initiate a run and generate test results. The system is expected to significantly reduce labor costs, minimize testing errors, improve operator ergonomics, and increase laboratory productivity.
Gen-Probe
(800) 523-5001; www.gen-probe.com
